Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$67.31 - $124.76 $673 - $1,247
10 Added 10.31%
107 $10,000
Q3 2023

Nov 13, 2023

SELL
$102.5 - $123.59 $102 - $123
-1 Reduced 1.02%
97 $11,000
Q1 2023

May 04, 2023

SELL
$117.53 - $155.99 $117 - $155
-1 Reduced 1.01%
98 $13,000
Q4 2022

Feb 06, 2023

BUY
$100.86 - $132.13 $100 - $132
1 Added 1.02%
99 $12,000
Q2 2022

Aug 04, 2022

SELL
$62.69 - $88.44 $3,698 - $5,217
-59 Reduced 37.58%
98 $7,000
Q1 2022

Aug 23, 2022

SELL
$63.15 - $90.42 $189 - $271
-3 Reduced 1.88%
157 $12,000
Q1 2022

Apr 14, 2022

SELL
$63.15 - $90.42 $2,020 - $2,893
-32 Reduced 16.67%
160 $12,000
Q4 2021

Feb 14, 2022

BUY
$77.28 - $99.42 $1,622 - $2,087
21 Added 12.28%
192 $17,000
Q3 2021

Nov 10, 2021

BUY
$65.97 - $92.48 $5,277 - $7,398
80 Added 87.91%
171 $16,000
Q2 2021

Aug 04, 2021

BUY
$69.38 - $86.75 $5,827 - $7,287
84 Added 1200.0%
91 $7,000
Q1 2021

May 05, 2021

SELL
$72.25 - $168.95 $6,358 - $14,867
-88 Reduced 92.63%
7 $1,000
Q4 2020

Feb 04, 2021

BUY
$125.56 - $178.74 $7,031 - $10,009
56 Added 143.59%
95 $16,000
Q3 2020

Nov 09, 2020

BUY
$127.12 - $172.34 $381 - $517
3 Added 8.33%
39 $5,000
Q2 2020

Aug 06, 2020

BUY
$93.0 - $171.7 $1,767 - $3,262
19 Added 111.76%
36 $6,000
Q1 2020

May 12, 2020

BUY
$82.38 - $131.64 $411 - $658
5 Added 41.67%
17 $2,000
Q2 2019

Aug 08, 2019

SELL
$112.21 - $151.95 $112 - $151
-1 Reduced 7.69%
12 $2,000
Q1 2019

May 10, 2019

BUY
$106.67 - $151.68 $1,386 - $1,971
13 New
13 $2,000
Q4 2018

Feb 06, 2019

SELL
$97.32 - $148.76 $486 - $743
-5 Closed
0 $0
Q4 2017

Feb 06, 2018

BUY
$47.64 - $56.75 $238 - $283
5
5 $0

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Glassman Wealth Services Portfolio

Follow Glassman Wealth Services and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

News

Stay updated on Glassman Wealth Services with notifications on news.